

# Graphene-Enhanced Electrochemical DNA Scaffold-based Biosensors for Point-of-Care Serology

---

**Jose Marrugo-Ramírez<sup>1</sup>**

Leyla Karadurmus<sup>1</sup>, Laura Gracia<sup>1</sup>, Miguel Berenguel<sup>1</sup>, Qiuyue Yang<sup>2</sup>, Enric Calucho<sup>7</sup>, Elisenda Santaló Ferrer<sup>7</sup>, Maryam Shafie Zadeh<sup>7</sup>, Ana Chopo<sup>2,3</sup>, Eliana Lodi<sup>1,2</sup>, Lourdes Rivas<sup>2</sup>, Luis Pires<sup>1,4</sup>, Miguel Vilaplana<sup>1</sup>, Jose Muñoz<sup>2,3,5,6</sup>, Natalia Rodríguez<sup>2,3,4</sup>, Joan Comenge<sup>10</sup>, Víctor Puentes<sup>8,9,10,11</sup>, Claudio Parolo<sup>2,7</sup>, Cláudia Simão Delgado<sup>1</sup>

<sup>1</sup> GraphenicaLab S.L., Tecnocampus, Edifici TCM6, Passatge Antoni Macià i Fonoll, 23, Door C, 08032 Mataró, Barcelona, Spain

<sup>2</sup> ISGlobal, Barcelona, Spain.

<sup>3</sup> Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain

<sup>4</sup> Department of Physics, University of Aveiro, Aveiro, Portugal.

<sup>5</sup> CIBERINFEC, ISCIII - CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Madrid, Spain.

<sup>6</sup> International Health Department, Hospital Clinic de Barcelona, Barcelona, Spain

<sup>7</sup> INTERFIBIO Research Group, Departament d'Enginyeria Química, Universitat Rovira i Virgili, Tarragona, Spain

<sup>8</sup> Instiut Català de Nanociència i Nanotecnologia (ICN2), 08193 Barcelona, Spain

<sup>9</sup> CSIC and The Barcelona Institute of Science and Technology (BIST), 08193 Barcelona, Spain

<sup>10</sup> Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain

<sup>11</sup> Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain

[claudia.simao@graphenicalab.com](mailto:claudia.simao@graphenicalab.com)

---

## Abstract

In a globalised world, it is increasingly important to refine and simplify vaccination decision-making by providing reliable, cost-effective, and eco-friendly serological testing directly at the point of care (PoC). A particular focus has been on diseases such as measles, HAV, and dengue; the project aims to yield significant public health benefits, including creating personalised vaccination strategies, reducing patient wait times, and improving global health outcomes, especially in international travel medicine. This initiative presents a constructive approach to enhancing public health infrastructure and responsiveness in a rapidly changing global landscape.

Focused on detecting antibodies for vaccine-preventable diseases such as measles, hepatitis A (HAV), and dengue, several sensor approaches have been reported for electrochemical detection using DNA-based sensors (E-DNA).<sup>[1,2]</sup> By integrating a DNA scaffold modified with a redox reporter and specific epitopes, the project introduces a new methodology for antibody detection. In this system, when antibodies are absent, the redox reporter interacts freely with the electrode, generating a measurable electrochemical signal. However, the binding of antibodies to their target epitopes creates steric hindrance, which reduces the interaction between the reporter and the electrode, resulting in a detectable decrease in the signal. This streamlined, single-step diagnostic test is designed for implementation in international travel clinics, enabling efficient assessments of immune status that support targeted vaccination strategies while reducing dependence on conventional, time-consuming serological methods. In this work, a thorough analysis of the state of the art is reported to understand the most promising immunologic systems and the key open challenges for integration in PoC solutions.

---


## References

---

- [1] White, R.J., Kallewaard, H.M., Hsieh, W., et al., *Anal. Chem.*, 2 (2011) 1098-1103  
[2] Parolo, C., Greenwood, A.S., Ogden, N.E., et al., *Microsyst. Nanoeng.*, 6 (2020)
- 

## Figures

---



**Figure 1:** A) The SerDNA project aims to develop a rapid diagnostic test able to measure multiple clinically relevant antibodies at the point of care to optimise the vaccination of individual patients. B) We will target three vaccine-preventable diseases: Measles, Hepatitis A and Dengue. C) The sensing concept relies on the use of E-DNA scaffold sensors, given their ability to measure antibodies in a single step and in less than 5 minutes. D) In order to maximise the analytical performance of E-DNA scaffold sensors, they will be integrated into environmentally friendly graphene-based electrodes modified with nanoparticles synthesised for this specific project.